Rank #1278KURA

Kura Oncology, Inc.

$8.58

1.06% (Daily)

Market Cap

$746.61M

Revenue

$104.03M

Rank by MCap

#1278

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Troy Edward Wilson J.D., Ph.D.

Headquarters

San Diego, CA

Employees

192

About Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNS...